Supreme Court Explains 7 Sub-Rights that Must be Protected by State During Land Acquisition  ||  SC: Accused Can’t be Arrested by ED After Special Court has Taken Cognizance of PMLA Complaint  ||  SC: Employees Filing Writ Petitions Against Air India After its Privatisation, Not Maintainable  ||  SC: UP Anti-Conversion Law May Seem to be Violating Article 25 of Constitution of India  ||  SC: UP Anti-Conversion Law May Seem to be Violating Article 25 of Constitution of India  ||  Kerala High Court: Power to Add Charges Remains With Court, Can’t be Done at Behest of Parties  ||  Allahabad High Court: Can’t Allow Petition for Expeditious Disposal of Cases on Regular Basis  ||  SC: Can’t Consider Payment of Compensation A Factor to Reduce Sentence of Convict  ||  SC: No Need for PMLA Acc. to Fulfill S. 45 Conditions When Furnis. Bond After Appearing Before Court  ||  Plea to Terminate 30 Weeks Pregnancy Dismissed, SC Talks About Right to Life of Child in Womb    

Why drugs are being taken off pharmacy shelves - (21 Mar 2016)

Civil

Headlines in recent days and weeks have reported hundreds, even thousands of drugs being banned from sale in India. Pharmacists are warning of shortages, a kinder way of saying rising prices, while also informing the Drug Controller General of India of the heightening probability of closure of shops, a.k.a., a strike. But why the sudden onset hostility towards certain medicines?

The banning of drugs may seem to have sprung out of the blue but there is method in the pharmacophobia. Circa June of 2013, the Directorate General of Health Services, under the auspices of the Ministry of Health and Family Welfare, released a report, ‘Policy Guidelines for Approval of Fixed Dose Combinations (FDCs) in India’. Prepared under the aegis of Professor C.K. Kokate, the Report considered the prevalence of ‘Fixed Dose Combination’, drugs comprising two or more active ingredients in a fixed ratio. The rationale behind FDCs is simple: two or more ‘actives’ that complement each other or provide the benefit of two products in one swallowing. But, to ensure FDCs’ benefits outweighing their risks, the Report called for called such preparations being based on “convincing therapeutic rationalization and be carefully justified and clinically relevant.” Categories of FDCs were penned and the onus was on manufacturers to show the rationale behind having two or more active ingredients in one preparation.

The Report birthed the ‘Kokate Committee’: tasked with the implementation of recommendations in the report, the Committee has spent over one year perusing thousands of drugs. As of January 2015, the Committee had found only 42.07 per cent of FDCs submitted for perusal as rational, and over 30 per cent as requiring further data or deliberation.

Tags : MINISTRY OF HEALTH   FIXED DOSE COMBINATIONS   RATIONALE  

Share :        

Disclaimer | Copyright 2024 - All Rights Reserved